
Please try another search
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Paul B. Manning | 67 | 2018 | Independent Chairman |
Paul-Peter Tak | 61 | 2020 | President, CEO & Director |
Charu Aggarwal | - | - | Member of Scientific Advisory Board |
James Patrick Allison | - | 2021 | Member of Research Advisory Board |
Daniel H. Sterman | - | - | Member of Scientific Advisory Board |
E. Antonio Chiocca | - | - | Member of Scientific Advisory Board |
Steven M. Albelda | - | - | Member of Scientific Advisory Board |
Christopher Martell | 45 | 2018 | Independent Director |
Roy Steven Herbst | 61 | 2021 | Member of Research Advisory Board |
Scott Eggener | - | - | Member of Scientific Advisory Board |
Adam Kibel | - | - | Member of Scientific Advisory Board |
Henry Brem | 71 | 2021 | Member of Research Advisory Board |
Elizabeth M. Jaffee | - | 2025 | Member of Research Advisory Board |
Philip W. Kantoff | 70 | 2021 | Member of Research Advisory Board |
Padmanee Sharma | - | 2021 | Member of Research Advisory Board |
Renee M. Gaeta | 44 | 2022 | Independent Director |
Diem Nguyen | 52 | 2021 | Independent Director |
Edward John Benz | 79 | 2017 | Member of Research Advisory Board & Independent Director |
Gary J. Nabel | 70 | 2022 | Member of Research Advisory Board & Independent Director |
Joseph C. Papa | 69 | 2022 | Independent Director |
Nicoletta Loggia | 57 | 2023 | Independent Director |
Mahalakshmi Radhakrishnan | 55 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review